RNAi for Therapeutic Market Report

Europe RNAi for Therapeutic Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 25, 2020
  • PAGES：168
  • REPORT CODE：GMM583820
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

    The RNAi for Therapeutic market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.7% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe RNAi for Therapeutic Market Segmentations:

    By Player:

    • Alnylam Pharmaceuticals

    • miRagen Therapeutics

    • RXi Pharmaceuticals

    • Quark Pharmaceuticals

    • Mirna Therapeutics

    • Gradalis

    • Arrowhead

    • Dicerna Pharmaceuticals

    • Sirnaomics

    By Type:

    • siRNA

    • miRNA

    • shRNA

    By End-User:

    • Cancer

    • Cardiovascular

    • HBV

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of RNAi for Therapeutic Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe RNAi for Therapeutic Market Size and Growth Rate of siRNA from 2014 to 2026

    • 1.3.2 Europe RNAi for Therapeutic Market Size and Growth Rate of miRNA from 2014 to 2026

    • 1.3.3 Europe RNAi for Therapeutic Market Size and Growth Rate of shRNA from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe RNAi for Therapeutic Market Size and Growth Rate of Cancer from 2014 to 2026

    • 1.4.2 Europe RNAi for Therapeutic Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • 1.4.3 Europe RNAi for Therapeutic Market Size and Growth Rate of HBV from 2014 to 2026

    • 1.4.4 Europe RNAi for Therapeutic Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of RNAi for Therapeutic Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of RNAi for Therapeutic by Major Types

      • 3.4.1 Market Size and Growth Rate of siRNA

      • 3.4.2 Market Size and Growth Rate of miRNA

      • 3.4.3 Market Size and Growth Rate of shRNA

    4 Segmentation of RNAi for Therapeutic Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of RNAi for Therapeutic by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Cancer for Construction

      • 4.4.2 Market Size and Growth Rate of Cardiovascular for Construction

      • 4.4.3 Market Size and Growth Rate of HBV for Construction

      • 4.4.4 Market Size and Growth Rate of Others for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe RNAi for Therapeutic Production Analysis by Top Regions

    • 5.2 Europe RNAi for Therapeutic Consumption Analysis by Top Regions

    • 5.3 Europe RNAi for Therapeutic Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.2 UK RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.3 France RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    6 Product Circulation of RNAi for Therapeutic Market among Top Countries

    • 6.1 Top 5 Export Countries in RNAi for Therapeutic Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in RNAi for Therapeutic Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in RNAi for Therapeutic Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in RNAi for Therapeutic Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in RNAi for Therapeutic Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in RNAi for Therapeutic Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany RNAi for Therapeutic Landscape Analysis

    • 7.1 Germany RNAi for Therapeutic Landscape Analysis by Major Types

    • 7.2 Germany RNAi for Therapeutic Landscape Analysis by Major End-Users

    8. UK RNAi for Therapeutic Landscape Analysis

    • 8.1 UK RNAi for Therapeutic Landscape Analysis by Major Types

    • 8.2 UK RNAi for Therapeutic Landscape Analysis by Major End-Users

    9. France RNAi for Therapeutic Landscape Analysis

    • 9.1 France RNAi for Therapeutic Landscape Analysis by Major Types

    • 9.2 France RNAi for Therapeutic Landscape Analysis by Major End-Users

    10. Italy RNAi for Therapeutic Landscape Analysis

    • 10.1 Italy RNAi for Therapeutic Landscape Analysis by Major Types

    • 10.2 Italy RNAi for Therapeutic Landscape Analysis by Major End-Users

    11. Spain RNAi for Therapeutic Landscape Analysis

    • 11.1 Spain RNAi for Therapeutic Landscape Analysis by Major Types

    • 11.2 Spain RNAi for Therapeutic Landscape Analysis by Major End-Users

    12. Poland RNAi for Therapeutic Landscape Analysis

    • 12.1 Poland RNAi for Therapeutic Landscape Analysis by Major Types

    • 12.2 Poland RNAi for Therapeutic Landscape Analysis by Major End-Users

    13. Russia RNAi for Therapeutic Landscape Analysis

    • 13.1 Russia RNAi for Therapeutic Landscape Analysis by Major Types

    • 13.2 Russia RNAi for Therapeutic Landscape Analysis by Major End-Users

    14. Switzerland RNAi for Therapeutic Landscape Analysis

    • 14.1 Switzerland RNAi for Therapeutic Landscape Analysis by Major Types

    • 14.2 Switzerland RNAi for Therapeutic Landscape Analysis by Major End-Users

    15. Turkey RNAi for Therapeutic Landscape Analysis

    • 15.1 Turkey RNAi for Therapeutic Landscape Analysis by Major Types

    • 15.2 Turkey RNAi for Therapeutic Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Landscape Analysis by Top Countries

      • 16.3.1 Denmark RNAi for Therapeutic Market Volume and Growth Rate

      • 16.3.2 Finland RNAi for Therapeutic Market Volume and Growth Rate

      • 16.3.3 Norway RNAi for Therapeutic Market Volume and Growth Rate

      • 16.3.4 Sweden RNAi for Therapeutic Market Volume and Growth Rate

      • 16.3.6 Iceland RNAi for Therapeutic Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Landscape Analysis by Top Countries

      • 17.3.1 Belgium RNAi for Therapeutic Market Volume and Growth Rate

      • 17.3.2 Netherlands RNAi for Therapeutic Market Volume and Growth Rate

      • 17.3.3 Luxembourg RNAi for Therapeutic Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Landscape Analysis by Top Countries

      • 18.3.1 Estonia RNAi for Therapeutic Market Volume and Growth Rate

      • 18.3.2 Latvia RNAi for Therapeutic Market Volume and Growth Rate

      • 18.3.3 Lithuania RNAi for Therapeutic Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Alnylam Pharmaceuticals

      • 19.1.1 Alnylam Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 miRagen Therapeutics

      • 19.2.1 miRagen Therapeutics Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 RXi Pharmaceuticals

      • 19.3.1 RXi Pharmaceuticals Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Quark Pharmaceuticals

      • 19.4.1 Quark Pharmaceuticals Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Mirna Therapeutics

      • 19.5.1 Mirna Therapeutics Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Gradalis

      • 19.6.1 Gradalis Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Arrowhead

      • 19.7.1 Arrowhead Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Dicerna Pharmaceuticals

      • 19.8.1 Dicerna Pharmaceuticals Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Sirnaomics

      • 19.9.1 Sirnaomics Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    The List of Tables and Figures (Totals 116 Figures and 174 Tables)

    • Figure Product Picture

    • Figure RNAi for Therapeutic Market Size and Growth Rate of siRNA Market, 2015 - 2026 (USD Million)

    • Figure RNAi for Therapeutic Market Size and Growth Rate of miRNA Market, 2015 - 2026 (USD Million)

    • Figure RNAi for Therapeutic Market Size and Growth Rate of shRNA Market, 2015 - 2026 (USD Million)

    • Figure RNAi for Therapeutic Market Size and Growth Rate of Cancer from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of HBV from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure UK RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure France RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Italy RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Spain RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Poland RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Russia RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Canada RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Finland RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Norway RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania RNAi for Therapeutic Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of RNAi for Therapeutic Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of RNAi for Therapeutic

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of RNAi for Therapeutic by Different Types from 2014 to 2026

    • Table Consumption Share of RNAi for Therapeutic by Different Types from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of siRNA Market, 2015 - 2026 (USD Million)

    • Figure RNAi for Therapeutic Market Size and Growth Rate of miRNA Market, 2015 - 2026 (USD Million)

    • Figure RNAi for Therapeutic Market Size and Growth Rate of shRNA Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of RNAi for Therapeutic by Different End-Users from 2014 to 2026

    • Table Consumption Share of RNAi for Therapeutic by Different End-Users from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of Cancer from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of HBV from 2014 to 2026

    • Figure RNAi for Therapeutic Market Size and Growth Rate of Others from 2014 to 2026

    • Table Europe RNAi for Therapeutic Production by Major Regions

    • Table Europe RNAi for Therapeutic Production Share by Major Regions

    • Figure Europe RNAi for Therapeutic Production Share by Major Countries and Regions in 2014

    • Table Europe RNAi for Therapeutic Consumption by Major Regions

    • Table Europe RNAi for Therapeutic Consumption Share by Major Regions

    • Table Germany RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table UK RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table France RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Italy RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Spain RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Poland RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Russia RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Switzerland RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Turkey RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in RNAi for Therapeutic Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in RNAi for Therapeutic Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in RNAi for Therapeutic Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in RNAi for Therapeutic Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Germany RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Germany RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Germany RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table UK RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table UK RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table UK RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table UK RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table France RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table France RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table France RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table France RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Italy RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Italy RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Italy RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Italy RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Spain RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Spain RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Spain RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Spain RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Poland RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Poland RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Poland RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Poland RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Russia RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Russia RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Russia RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Russia RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Switzerland RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Switzerland RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Switzerland RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Turkey RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Turkey RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Turkey RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Turkey RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) RNAi for Therapeutic Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) RNAi for Therapeutic Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) RNAi for Therapeutic Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries RNAi for Therapeutic Market Volume and Growth Rate from 2014 to 2026

    • Table Alnylam Pharmaceuticals Profiles

    • Table Alnylam Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Alnylam Pharmaceuticals Product benchmarking

    • Table Alnylam Pharmaceuticals Strategic initiatives

    • Table Alnylam Pharmaceuticals SWOT analysis

    • Table miRagen Therapeutics Profiles

    • Table miRagen Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table miRagen Therapeutics Product benchmarking

    • Table miRagen Therapeutics Strategic initiatives

    • Table miRagen Therapeutics SWOT analysis

    • Table RXi Pharmaceuticals Profiles

    • Table RXi Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table RXi Pharmaceuticals Product benchmarking

    • Table RXi Pharmaceuticals Strategic initiatives

    • Table RXi Pharmaceuticals SWOT analysis

    • Table Quark Pharmaceuticals Profiles

    • Table Quark Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Quark Pharmaceuticals Product benchmarking

    • Table Quark Pharmaceuticals Strategic initiatives

    • Table Quark Pharmaceuticals SWOT analysis

    • Table Mirna Therapeutics Profiles

    • Table Mirna Therapeutics Production, Value, Price, Gross Margin 2014-2019

    • Table Mirna Therapeutics Product benchmarking

    • Table Mirna Therapeutics Strategic initiatives

    • Table Mirna Therapeutics SWOT analysis

    • Table Gradalis Profiles

    • Table Gradalis Production, Value, Price, Gross Margin 2014-2019

    • Table Gradalis Product benchmarking

    • Table Gradalis Strategic initiatives

    • Table Gradalis SWOT analysis

    • Table Arrowhead Profiles

    • Table Arrowhead Production, Value, Price, Gross Margin 2014-2019

    • Table Arrowhead Product benchmarking

    • Table Arrowhead Strategic initiatives

    • Table Arrowhead SWOT analysis

    • Table Dicerna Pharmaceuticals Profiles

    • Table Dicerna Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

    • Table Dicerna Pharmaceuticals Product benchmarking

    • Table Dicerna Pharmaceuticals Strategic initiatives

    • Table Dicerna Pharmaceuticals SWOT analysis

    • Table Sirnaomics Profiles

    • Table Sirnaomics Production, Value, Price, Gross Margin 2014-2019

    • Table Sirnaomics Product benchmarking

    • Table Sirnaomics Strategic initiatives

    • Table Sirnaomics SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US